Streetbeat News

Stock Prices

TMO

Thermo Fisher Scientific Inc. (NYSE:TMO) is currently trading at $516.30, after a 0.11% drop. Over the past month, the stock fell by 1.71%, and in the past year, by 1.06%. The company's price-to-earnings (P/E) ratio is lower than the aggregate P/E of 45.05 of the Life Sciences Tools & Services industry, which could indicate that the stock is undervalued or that shareholders do not expect future growth.

Portfolio Pulse from Benzinga Insights

July 11, 2023 | 1:46 pm

ELOX

Trading of Eloxx Pharmaceuticals' shares has resumed.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 1:42 pm

ABNB

Airbnb bookings have declined in cities like Austin and San Francisco, causing concerns over a potential 'doom loop'. Revenues are reportedly down nearly 50% in cities like Phoenix and Austin, according to Reventure Consulting. However, Airbnb and AirDNA dispute these figures, stating that the decline is not as severe. The decline in bookings is attributed to the end of pandemic-era migration and a decrease in the number of people working from home. The San Francisco Standard reported a 29% decrease in nights stayed in vacation rentals in San Francisco in May 2023 compared to May 2019.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:42 pm

BTTX

Better Therapeutics Inc's (NASDAQ:BTTX) shares are trading higher after the FDA approved AspyreRx, a prescription-only digital treatment for type 2 diabetes. The product is expected to launch in Q4 2023. The approval was based on a trial involving 668 participants, which showed significant decreases in HbA1c levels. The company's shares are up 45.60% at $1.31.

Portfolio Pulse from Vandana Singh

July 11, 2023 | 1:40 pm

CHH

Choice Hotels International Inc (CHH) has provided an update on its strategy and 2023 and 2024 guidance. The company is expanding its franchise business and has exceeded its synergy targets with the integration of Radisson Hotels Americas. CHH has opened 107 hotels in 2023, a 39% increase YoY. The company reiterated its 2023 outlook and expects a 10% YoY growth in adjusted EBITDA for 2024. CHH also repurchased around 1.8 million shares worth over $220 million in H1 2023.

Portfolio Pulse from Lekha Gupta

July 11, 2023 | 1:40 pm

ELOX

Shares of Eloxx Pharmaceuticals were halted on a circuit breaker to the upside, with the stock now up by 31.7%.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:39 pm

BRTX

BioRestorative Therapies Inc (BRTX) shares dropped by 17.13% after the company announced a $2.1 million registered direct offering. The offering is for the sale of 685,033 shares at $3.03 per share. The proceeds will be used for clinical trials, pre-clinical research and development, and general corporate purposes.

Portfolio Pulse from Henry Khederian

July 11, 2023 | 1:36 pm

BTCUSD

ETHUSD

WBTCUSD

XECUSD

Bitcoin (BTC) and Ethereum (ETH) traded higher, with BTC above the $30,400 level and ETH above the $1,800 mark. Wrapped Bitcoin (WBTC) was the top gainer over the prior 24 hours, while eCash (XEC) was the biggest loser. The global crypto market cap rose to $1.18 trillion, recording a 24-hour gain of 0.9%. Other notable gainers include Solana (SOL), Compound (COMP), Polygon (MATIC), and Mina (MINA). Losers include Nexo (NEXO), Monero (XMR), Toncoin (TON), and Algorand (ALGO).

Portfolio Pulse from Lisa Levin

July 11, 2023 | 1:36 pm

CING

Cingulate Inc (NASDAQ:CING) shares are trading higher following the announcement of positive topline results from its Phase 3 adult trial of lead candidate, CTx-1301, for attention-deficit/hyperactivity disorder (ADHD). The data showed a significant trend in improving ADHD symptoms. The company plans to initiate its pivotal Phase 3 fixed-dose pediatric and adolescent study this month and a dose-optimization onset and duration trial in pediatric patients in August 2023. Assuming positive results, Cingulate plans to submit a New Drug Application for CTx-1301 in mid-2024.

Portfolio Pulse from Vandana Singh

July 11, 2023 | 1:33 pm

IOVA

Iovance Biotherapeutics Inc's shares are trading lower after the company announced the pricing of a public offering of 20 million shares at $7.50 per share, expected to raise approximately $150 million. The proceeds will be used to fund preparations for the commercial launch of lifileucel, support the development of the company's pipeline candidates, and support Proleukin integration activities. Despite the drop, Truist Securities and Chardan Capital analysts reiterated a Buy rating for Iovance, with price targets of $17 and $29 respectively.

Portfolio Pulse from Adam Eckert

July 11, 2023 | 1:30 pm